Market Size of Myasthenia Gravis Therapeutics Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 6.20 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Myasthenia Gravis Therapeutics Market Analysis
Myasthenia gravis (MG) is a long-term neuromuscular disease that leads to varying degrees of skeletal muscle weakness. Muscles of the eyes, face, and swallowing are the most commonly affected muscles in the body. The weakening of these muscles can result in double vision, drooping eyelids, trouble talking, and trouble walking. Although a rare disease, the prevalence of the disease has increased over the past few decades, as per National Organization for Rare Disorders. As a result, the research and development in understanding the disease and finding a cure have also increased. these factors have helped this market grow.
However, the cost of treatment still remains high for the disease. This has been restraining the market growth.
Myasthenia Gravis Therapeutics Industry Segmentation
Myasthenia gravis is a neuromuscular autoimmune disorder that causes weakness in the skeletal muscles, which are the muscles your body uses for movement. It occurs when communication between nerve cells and muscles becomes impaired. This impairment prevents crucial muscle contractions from occurring, resulting in muscle weakness. Although there is no cure for the disorder, medications may be used to prevent the exacerbation of symptoms.
| By Treatment | |
| Medication | |
| Surgery | |
| Others |
| By End-User | |
| Hospitals | |
| Clinics | |
| Others |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Myasthenia Gravis Therapeutics Market Size Summary
The Myasthenia Gravis Therapeutics Market is experiencing growth driven by increased research and development efforts aimed at understanding and treating this rare neuromuscular disease. Myasthenia gravis leads to muscle weakness, particularly affecting the eyes, face, and swallowing muscles, and its prevalence has risen over the past few decades. Despite the high cost of treatment posing a challenge to market expansion, the development of therapies such as acetylcholinesterase inhibitors and immunosuppressive agents has been pivotal. These treatments aim to enhance acetylcholine availability at the neuromuscular junction and address immune dysregulation, respectively. The market is characterized by the dominance of global key players who invest significantly in research and have established robust distribution networks.
North America, particularly the United States and Canada, is a significant region for the myasthenia gravis therapeutics market due to its advanced healthcare systems and substantial investment in rare disease research. The availability of medical insurance in these countries enables patients to access costly treatments, contributing to the region's large market share. Additionally, the presence of major pharmaceutical companies in North America supports market growth. Meanwhile, the Asia-Pacific region is witnessing the emergence of smaller players, driven by increased awareness, further contributing to market expansion. Companies like Alexion Pharmaceuticals Inc, Mitsubishi Tanabe Pharma, and UCB S.A. are key players in this market landscape.
Myasthenia Gravis Therapeutics Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Rising Incidence of Myasthenia Gravis
-
1.2.2 Increasing Research and Development for Myasthenia Gravis
-
-
1.3 Market Restraints
-
1.3.1 High Cost of Treatment
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Treatment
-
2.1.1 Medication
-
2.1.2 Surgery
-
2.1.3 Others
-
-
2.2 By End-User
-
2.2.1 Hospitals
-
2.2.2 Clinics
-
2.2.3 Others
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle-East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle-East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Myasthenia Gravis Therapeutics Market Size FAQs
What is the current Myasthenia Gravis Therapeutics Market size?
The Myasthenia Gravis Therapeutics Market is projected to register a CAGR of 6.20% during the forecast period (2024-2029)
Who are the key players in Myasthenia Gravis Therapeutics Market?
Alexion Pharmaceuticals Inc, Mitsubishi Tanabe Pharma, Astellas Pharma, Bausch Health and UCB S.A. are the major companies operating in the Myasthenia Gravis Therapeutics Market.
